PSMA
-
Bayer Unveils Promising Data on Investigational ²²⁵Ac-PSMA-Trillium for Advanced Metastatic Prostate Cancer
Bayer’s investigational therapy, ²²⁵Ac-PSMA-Trillium, shows promise for advanced prostate cancer. This targeted radionuclide therapy uses alpha-emitting ²²⁵Ac and a PSMA-targeting ligand to attack cancer cells. Clinical trial results are being reviewed for efficacy, safety, and commercial viability. The therapy could position Bayer as a leader in radiopharmaceuticals, though manufacturing and cost challenges remain. It represents a significant advancement beyond standard treatments, offering hope for overcoming resistance and improving patient outcomes.
-
VIR-5500: Promising Phase 1 Update for Metastatic Prostate Cancer Patients
Vir Biotechnology’s VIR-5500, a novel T-cell engager for advanced prostate cancer, showed promising safety and anti-tumor activity in Phase 1 trials. The therapy demonstrated significant PSA declines and objective responses in heavily pre-treated patients, with manageable side effects. This dual-targeting approach, utilizing PRO-XTEN® masking, aims for a differentiated therapeutic index, potentially offering a new option for patients with limited treatment choices.
